BerGenBio ASA (OSL:BGBIO) FCF Margin % : -25,533.53% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BerGenBio ASA's Free Cash Flow for the three months ended in Mar. 2024 was kr-42.64 Mil. BerGenBio ASA's Revenue for the three months ended in Mar. 2024 was kr0.17 Mil. Therefore, BerGenBio ASA's FCF Margin % for the quarter that ended in Mar. 2024 was -25,533.53%.

As of today, BerGenBio ASA's current FCF Yield % is -44.64%.

The historical rank and industry rank for BerGenBio ASA's FCF Margin % or its related term are showing as below:

OSL:BGBIO' s FCF Margin % Range Over the Past 10 Years
Min: -74095.37 Med: -39092.86 Max: -2097.56
Current: -35200

During the past 9 years, the highest FCF Margin % of BerGenBio ASA was -2097.56%. The lowest was -74095.37%. And the median was -39092.86%.

OSL:BGBIO's FCF Margin % is ranked worse than
96.25% of 1040 companies
in the Biotechnology industry
Industry Median: -137.43 vs OSL:BGBIO: -35200.00

BerGenBio ASA FCF Margin % Historical Data

The historical data trend for BerGenBio ASA's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA FCF Margin % Chart

BerGenBio ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,097.56

-38,994.51

-39,191.21

-74,095.37

-63,587.85

BerGenBio ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-6,244.92	-25,533.53

Competitive Comparison of BerGenBio ASA's FCF Margin %

For the Biotechnology subindustry, BerGenBio ASA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BerGenBio ASA's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BerGenBio ASA's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BerGenBio ASA's FCF Margin % falls into.

BerGenBio ASA FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BerGenBio ASA's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-225.101	/	0.354
	=	-63,587.85 %

BerGenBio ASA's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-42.641	/	0.167
	=	-25,533.53 %

BerGenBio ASA FCF Margin % Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BerGenBio ASA (OSL:BGBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0RU5:UK 7BG0:Germany

Address

Mollendalsbakken 9, Bergen, NOR, 5009

Website

https://www.bergenbio.com

BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (OSL:BGBIO) Headlines

No Headlines